Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462026 | 0.85 | KMT2A (0.68) | KMT2AMEN1HRH3CHRNA7HTR2C | |
| SCHEMBL5474021 | 0.82 | MEN1 (0.76) | KMT2AMEN1ALDH1A1LMNAKDM4E | |
| SCHEMBL5465071 | 0.80 | MEN1 (1.00) | KMT2AMEN1POLBHRH3CHRNA7 | |
| SCHEMBL5464429 | 0.80 | MEN1 (0.60) | KMT2AMEN1ALDH1A1KDM4EPKM | |
| SCHEMBL5471326 | 0.79 | MEN1 (0.62) | KMT2AMEN1ALDH1A1HRH3HTR2C | |
| SCHEMBL5443674 | 0.78 | HRH3 (0.74) | KMT2AMEN1HRH3LMNA | |
| SCHEMBL4979069 | 0.78 | MCHR1 (0.52) | KMT2AMEN1ALDH1A1POLBHRH3 | |
| SCHEMBL5477357 | 0.77 | MEN1 (0.73) | KMT2AMEN1HRH3CHRNA7HTR2C | |
| SCHEMBL28466660 | 0.77 | MEN1 (0.78) | KMT2AMEN1ALDH1A1HRH3LMNA | |
| SCHEMBL5466273 | 0.76 | KMT2A (0.76) | KMT2AMEN1ALDH1A1POLBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | KMT2A 323/4885MEN1 3623/4885ALDH1A1 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.